The new guidelines aim to streamline India’s drug approvals, improve transparency, and align regulatory practices with global ...

Biodeal Pharmaceuticals Limited has been directed by the National Pharmaceutical Pricing Authority (NPPA) to submit documents ...

Despite the recent buzz, the effort to reduce animal testing in favor of NAMs has been underway for years. The VQN falls ...

Q2 2025 Earnings Call Transcript August 1, 2025 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

Costing more than $9 million and funded by U.S taxpayers, the family planning supplies were intended for women in war zones, ...

Six months into her first year as sheriff, Alyshia Dyer has seen crime drop and a continued focus on the social work values at the heart of her campaign. “After setting the new mission and values, we ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The Bangladesh Association of Pharmaceutical Industries (Bapi) has urged the government to fast-track the registration of over 1,000 new medicines pending with the Directorate General of Drug ...